MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer

British Journal of Cancer

Volumn 111, Issue 8, 2014, Pages 1572-1580

  Hasegawa, S ^a   Eguchi, H ^a   Nagano, H ^a   Konno, M ^a   Tomimaru, Y ^a   Wada, H ^a   Hama, N ^a   Kawamoto, K ^a   Kobayashi, S ^a   Nishida, N ^a   Koseki, J ^a   Nishimura, T ^b   Gotoh, N ^b   Ohno, S ^c   Yabuta, N ^c   Nojima, H ^c   Mori, M ^a   Doki, Y ^a   Ishii, H ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CCNG2 PROTEIN, HUMAN; CYCLIN G2; DEOXYCYTIDINE; GEMCITABINE; MICRORNA; MIRN1246 MICRORNA, HUMAN;

ANALOGS AND DERIVATIVES; ANIMAL; CANCER STEM CELL; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CYCLIN G2; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICRORNAS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS;

EID: 84908866562     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.454     Document Type: Article

References (27)

1. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA, Sarkar FH (2010) Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70: 3606-3617.
2. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
3. Bates S, Rowan S, Vousden KH (1996) Characterisation of human cyclin G1 and G2: DNA damage inducible genes. Oncogene 13: 1103-1109.
4. Chen J, Yao D, Zhao S, He C, Ding N, Li L, Long F (2014) MiR-1246 promotes SiHa cervical cancer cell proliferation, invasion, and migration through suppression of its target gene thrombospondin 2. Arch Gynecol Obstet (in press).
5. Chen JQ, Liu CJ, Wen HX, Shi CL, Zhang HS, Li M, Sun GG (2013) Changes in the expression of cyclin G2 in esophageal cancer cell and its significance. Tumour Biol 35: 3355-3362.
6. Choi MG, Noh JH, An JY, Hong SK, Park SB, Baik YH, Kim KM, Sohn TS, Kim S (2009) Expression levels of cyclin G2, but not cyclin E, correlate with gastric cancer progression. J Surg Res 157: 168-174.
7. Cui DW, Cheng YJ, Jing SW, Sun GG (2014a) Effect of cyclin G2 on proliferative ability of prostate cancer PC-3 cell. Tumour Biol 35: 3017-3024.
8. Cui DW, Sun GG, Cheng YJ (2014b) Change in expression of cyclin G2 in kidney cancer cell and its significance. Tumour Biol 35: 3177-3183.
9. Giovannetti E, FunelN, PetersGJ, DelChiaroM, Erozenci LA, Vasile E, Leon LG, Pollina LE, GroenA, Falcone A, Danesi R, CampaniD,Verheul HM, BoggiU (2010) MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70: 4528-4538.
10. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
11. Hoyert DL, Heron MP, Murphy SL, Kung HC (2006) Deaths: final data for 2003. Natl Vital Stat Rep 54: 1-120.
12. Ito Y, Yoshida H, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma K, Miyauchi A (2003) Decreased expression of cyclin G2 is significantly linked to the malignant transformation of papillary carcinoma of the thyroid. Anticancer Res 23: 2335-2338.
13. Iwagami Y, Eguchi H, Nagano H, Akita H, Hama N, Wada H, Kawamoto K, Kobayashi S, Tomokuni A, Tomimaru Y, Mori M, Doki Y (2013) miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer 109: 502-511.
14. Kasukabe T, Okabe-Kado J, Honma Y (2008) Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2. Cancer Sci 99: 1693-1698.
15. Kim Y, Shintani S, Kohno Y, Zhang R, Wong DT (2004) Cyclin G2 dysregulation in human oral cancer. Cancer Res 64: 8980-8986.
16. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007) Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037.
17. Li Y, VandenBoom II TG, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH (2009) Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-6712.
18. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcala S, Rodriguez-Arabaolaza I, Ramirez JC, Torres-Ruiz R, Garcia E, Hidalgo M, Cebrian DA, Heuchel R, Lohr M, Berger F, Bartenstein P, Aicher A, Heeschen C (2011) Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 9: 433-446.
19. Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, Basso G, Leo G, Rosato A, Bicciato S, Cordenonsi M, Piccolo S (2012) SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 487: 380-384.
20. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277.
21. Padua MB, Hansen PJ (2009) Changes in expression of cell-cycle-related genes in PC-3 prostate cancer cells caused by ovine uterine serpin. J Cell Biochem 107: 1182-1188.
22. Pastrana E, Silva-Vargas V, Doetsch F (2011) Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8: 486-498.
23. Sun GG, Hu WN, Cui DW, Zhang J (2014a) Decreased expression of CCNG2 is significantly linked to the malignant transformation of gastric carcinoma. Tumour Biol 35: 2631-2639.
24. Sun GG, Zhang J, Hu WN (2014b) CCNG2 expression is downregulated in colorectal carcinoma and its clinical significance. Tumour Biol 35: 3339-3346.
25. Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y, Ikeda N, Isozaki Y, Maruyama T, Akanuma N, Komatsu A, Jitsukawa M, Matsubara H (2013) Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer 108: 644-652.
26. Zhang XJ, Ye H, Zeng CW, He B, Zhang H, Chen YQ (2010) Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol 3: 46.
27. Zhao Z, Liu Y, He H, Chen X, Chen J, Lu YC (2011) Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine. Brain Res Bull 86: 189-194.